Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer – guidance (TA660)

Darolutamide with androgen deprivation therapy is recommended as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.

National Institute for Health and Care Excellence